Ethical issues in the use of genetic testing of patients with schizophrenia and their families

Current Opinion in Psychiatry

Volumn 27, Issue 3, 2014, Pages 191-196

  DeLisi, Lynn E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

DNA; ethics; genome; pharmacogenetics; prediction

Indexed keywords

CLOZAPINE;

BIOETHICS; FAMILY ATTITUDE; GENETIC PRIVACY; GENETIC RISK; GENETIC SCREENING; GOVERNMENT; HEALTH EDUCATION; HUMAN; HUMAN GENOME; INCIDENTAL FINDING; INTERNET; MATE CHOICE; MEDICAL INFORMATION; PATIENT ATTITUDE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHYSICIAN ATTITUDE; PRENATAL DIAGNOSIS; PRENATAL SCREENING; REVIEW; SCHIZOPHRENIA; TREATMENT RESPONSE;

BIOETHICAL ISSUES; ETHICS, MEDICAL; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MARKETING OF HEALTH SERVICES; SCHIZOPHRENIA;

EID: 84897109298     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000060     Document Type: Review

References (29)

1. Francke U, Dijamco C, Kiefer AK, et al. Dealing with the unexpected: consumer responses to direct-access BRCA mutation testing. Peer J 2013; 1:e8.
2. DeLisi LE, Bertisch H. A preliminary comparison of the hopes of researchers, clinicians, and families for the future ethical use of genetic findings on schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 110-115. (Pubitemid 43062551)
3. Austin JC, Hippman C, Honer WC. Descriptive and numeric estimation of risk for psychotic disorders among affected individuals and relatives: implications for clinical practice. Psychiatry Res 2012; 196:52-56.
4. Green RC, Roberts JS, Cupples LA, et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 2009; 361:245-254.
5. Ashida S, Koehly LM, Roberts JS, et al. The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study. Eur J Hum Genet 2010; 18:1296-1301.
6. Chao S, Roberts JS, Marteau TM, et al. Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord 2008; 22:94-97. (Pubitemid 351651404)
7. Vernarelli JA, Roberts JS, Hiraki S, et al. Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am J Clin Nutr 2010; 91:1402-1407.
8. Zick CD, Mathews CJ, Roberts JS, et al. Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff 2005; 24:483-490. (Pubitemid 40528968)
9. Salm M, Abbate K, Appelbaum P, et al. Use of genetic tests among neurologists and psychiatrists: knowledge, attitudes, behaviors, and needs for training. J Genet Couns 2013; PMCID:PMC3812264.
10. Austin JC. Reconceptualizing risk in genetic counseling: Implications for clinical practice. J Genet Counsel 2010; 319:228-234.
11. Hippman C, Lohn Z, Ringrose A, et al. Nothing is absolute in life': understanding uncertainty in the context of psychiatric genetic counseling from the prospective of those with serious mental illness. J Genet Counsel 2013; 22:625-632.
12. Lautenbach DM, Christensen KD, Sparks JA, et al. Communicating genetic risk information for common disorders in the era of genomic medicine. Annu Rev Genom Hum Genet 2013; 14:491-513.
13. Dudbridge F. Power and predictive accuracy of polygenic risk scores. PLoS Genet 2013; 9:e1003348.
14. Karayiorgou M, Morris MA, Morrow B, et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci U S A 1995; 92:7612-7616.
15. Vacic V, McCarthy S, Malhotra D, et al. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature 2011; 471:499-503.
16. Erratum in: Nature 2011; 474:114.
17. Xu B, Ionita-Laza I, Roos JL, et al. De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nat Genet 2012; 44:1365-1369.
18. Ripke S, O'Dushlaine C, Chambert K, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 2013; 45: 1150-1159.
19. Kohlrausch FB. Pharmacogenetics in schizophrenia: a review of clozapine studies. Revista Brasileira de Psiquiatria 2013; 35:305-317.
20. Shamy MCF, Zai C, Basile VS, et al. Ethical and policy considerations in the application of pharmacogenomic testing for Tardive Dyskinesia: case study of the dopamine D3 receptor. Curr Pharmacogenomics Person Med 2011; 9:94-101.
21. Zai CC, Tiwari AK, Mazzoco M, et al. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J Psychiatr Res 2013; 47:1760-1765.
22. Zhang J-P, Malhotra AK. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Exp Opin Drug Metab Toxicol 2011; 7:9-37.
23. Klitzman R, Appelbaum PS, Chung W. Return of secondary genomic findings versus patient autonomy: implications for medical care. JAMA 2013; 310: 369-370.
24. McGuire AL, Joffe S, Koenig BA, et al. Ethics and genomic incidental findings. Science 2013; 340:1047-1048.
25. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013; 15:565-574.
26. Appelbaum PS, Waldman CR, Fyer A, et al. Informed consent for return of incidental findings in genomic research. Genet Med 2013. [Epub ahead of print]
27. Malhotra D, Sebat J. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell 2012; 148:1223-1241.
28. Gershon ES, Alliey-Rodriguez N. New ethical issues for genetic counseling in common mental disorders. Am J Psychiatry 2013; 170:968-976.
29. Lifton R. The Nazi doctors: medical killing and the psychology of genocide. New York: Basic Books; 1986; pp. 1-552.